KEGG   PATHWAY: dnm05235
Entry
dnm05235                    Pathway                                
Name
PD-L1 expression and PD-1 checkpoint pathway in cancer - Dasypus novemcinctus (nine-banded armadillo)
Description
Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.
Class
Human Diseases; Cancer: overview
Pathway map
dnm05235  PD-L1 expression and PD-1 checkpoint pathway in cancer
dnm05235

Organism
Dasypus novemcinctus (nine-banded armadillo) [GN:dnm]
Gene
101443806  HIF1A; hypoxia-inducible factor 1-alpha isoform X1 [KO:K08268]
101418748  EGF; pro-epidermal growth factor isoform X1 [KO:K04357]
105746538  EGFR; epidermal growth factor receptor [KO:K04361] [EC:2.7.10.1]
101419480  HRAS; GTPase HRas isoform X1 [KO:K02833]
101412233  KRAS; GTPase KRas isoform X4 [KO:K07827]
101430817  NRAS; GTPase NRas [KO:K07828]
101414240  LOW QUALITY PROTEIN: GTPase NRas-like [KO:K07828]
101421211  RAF1; RAF proto-oncogene serine/threonine-protein kinase isoform X1 [KO:K04366] [EC:2.7.11.1]
101435268  MAP2K1; dual specificity mitogen-activated protein kinase kinase 1 isoform X1 [KO:K04368] [EC:2.7.12.2]
101420546  dual specificity mitogen-activated protein kinase kinase 2 [KO:K04369] [EC:2.7.12.2]
101430570  MAPK1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
101435742  MAPK3; mitogen-activated protein kinase 3 [KO:K04371] [EC:2.7.11.24]
101431782  FOS; proto-oncogene c-Fos [KO:K04379]
101412001  JUN; transcription factor AP-1 [KO:K04448]
101418354  EML4; echinoderm microtubule-associated protein-like 4 [KO:K15420]
101436525  ALK; ALK tyrosine kinase receptor [KO:K05119] [EC:2.7.10.1]
101423744  phosphatidylinositol 3-kinase regulatory subunit gamma [KO:K02649]
101435351  PIK3R1; phosphatidylinositol 3-kinase regulatory subunit alpha isoform X1 [KO:K02649]
101433347  PIK3R2; phosphatidylinositol 3-kinase regulatory subunit beta [KO:K02649]
101444276  PIK3CA; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [KO:K00922] [EC:2.7.1.153]
101443761  PIK3CD; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform isoform X1 [KO:K00922] [EC:2.7.1.153]
101426945  PIK3CB; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform [KO:K00922] [EC:2.7.1.153]
101445493  PTEN; phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN [KO:K01110] [EC:3.1.3.16 3.1.3.48 3.1.3.67]
101419022  AKT2; RAC-beta serine/threonine-protein kinase isoform X1 [KO:K04456] [EC:2.7.11.1]
101428799  AKT3; RAC-gamma serine/threonine-protein kinase isoform X1 [KO:K04456] [EC:2.7.11.1]
101445813  AKT1; RAC-alpha serine/threonine-protein kinase [KO:K04456] [EC:2.7.11.1]
101434069  MTOR; LOW QUALITY PROTEIN: serine/threonine-protein kinase mTOR [KO:K07203] [EC:2.7.11.1]
101439255  RPS6KB1; ribosomal protein S6 kinase beta-1 isoform X1 [KO:K04688] [EC:2.7.11.1]
101434210  RPS6KB2; ribosomal protein S6 kinase beta-2 [KO:K04688] [EC:2.7.11.1]
101429772  CHUK; inhibitor of nuclear factor kappa-B kinase subunit alpha isoform X1 [KO:K04467] [EC:2.7.11.10]
101411204  IKBKB; inhibitor of nuclear factor kappa-B kinase subunit beta isoform X1 [KO:K07209] [EC:2.7.11.10]
101439489  IKBKG; NF-kappa-B essential modulator isoform X1 [KO:K07210]
101412730  NFKBIA; LOW QUALITY PROTEIN: NF-kappa-B inhibitor alpha [KO:K04734]
101425701  NFKBIB; NF-kappa-B inhibitor beta [KO:K02581]
101437556  NFKB1; LOW QUALITY PROTEIN: nuclear factor NF-kappa-B p105 subunit [KO:K02580]
101417885  RELA; transcription factor p65 [KO:K04735]
101422877  IFNG; interferon gamma [KO:K04687]
101416634  IFNGR1; interferon gamma receptor 1 [KO:K05132]
101425494  IFNGR2; interferon gamma receptor 2 [KO:K05133]
101432776  JAK1; LOW QUALITY PROTEIN: tyrosine-protein kinase JAK1 [KO:K11217] [EC:2.7.10.2]
101416389  JAK2; tyrosine-protein kinase JAK2 [KO:K04447] [EC:2.7.10.2]
101436399  STAT1; signal transducer and activator of transcription 1-alpha/beta [KO:K11220]
101444225  STAT3; signal transducer and activator of transcription 3 isoform X1 [KO:K04692]
101421345  TLR2; toll-like receptor 2 [KO:K10159]
101436464  TLR4; toll-like receptor 4 [KO:K10160]
101415381  toll-like receptor 9 isoform X3 [KO:K10161]
101445854  TIRAP; toll/interleukin-1 receptor domain-containing adapter protein [KO:K05403]
101431630  MYD88; LOW QUALITY PROTEIN: myeloid differentiation primary response protein MyD88 [KO:K04729]
101438500  TRAF6; TNF receptor-associated factor 6 [KO:K03175] [EC:2.3.2.27]
101427882  NFATC1; LOW QUALITY PROTEIN: nuclear factor of activated T-cells, cytoplasmic 1 [KO:K04446]
101417008  NFATC2; nuclear factor of activated T-cells, cytoplasmic 2 isoform X1 [KO:K17332]
101424450  NFATC3; nuclear factor of activated T-cells, cytoplasmic 3 isoform X2 [KO:K17333]
101433765  TICAM1; TIR domain-containing adapter molecule 1 [KO:K05842]
101433072  TICAM2; TIR domain-containing adapter molecule 2 [KO:K05409]
101414633  CD274; programmed cell death 1 ligand 1 [KO:K06745]
101435928  PDCD1; programmed cell death protein 1 [KO:K06744]
101435353  PTPN6; tyrosine-protein phosphatase non-receptor type 6 [KO:K05697] [EC:3.1.3.48]
101435063  PTPN11; tyrosine-protein phosphatase non-receptor type 11 isoform X2 [KO:K07293] [EC:3.1.3.48]
101437864  BATF2; basic leucine zipper transcriptional factor ATF-like 2 [KO:K09034]
101421192  BATF3; basic leucine zipper transcriptional factor ATF-like 3 isoform X1 [KO:K09034]
101434120  BATF; basic leucine zipper transcriptional factor ATF-like [KO:K09034]
101413366  CSNK2A1; casein kinase II subunit alpha [KO:K03097] [EC:2.7.11.1]
101423354  CSNK2A2; casein kinase II subunit alpha' [KO:K03097] [EC:2.7.11.1]
101438650  CSNK2B; casein kinase II subunit beta [KO:K03115]
101411381  CD4; T-cell surface glycoprotein CD4 isoform X1 [KO:K06454]
101445129  LCK; tyrosine-protein kinase Lck [KO:K05856] [EC:2.7.10.2]
101421796  CD3E; T-cell surface glycoprotein CD3 epsilon chain [KO:K06451]
101412450  CD3G; T-cell surface glycoprotein CD3 gamma chain isoform X1 [KO:K06452]
101425248  CD247; T-cell surface glycoprotein CD3 zeta chain isoform X1 [KO:K06453]
101413471  CD3D; T-cell surface glycoprotein CD3 delta chain [KO:K06450]
101423099  tyrosine-protein kinase ZAP-70 isoform X1 [KO:K07360] [EC:2.7.10.2]
101410864  MAP3K3; mitogen-activated protein kinase kinase kinase 3 [KO:K04421] [EC:2.7.11.25]
101431376  MAP2K6; dual specificity mitogen-activated protein kinase kinase 6 [KO:K04433] [EC:2.7.12.2]
101425795  MAPK14; mitogen-activated protein kinase 14 isoform X1 [KO:K04441] [EC:2.7.11.24]
101426841  MAPK13; mitogen-activated protein kinase 13 isoform X2 [KO:K04441] [EC:2.7.11.24]
101415496  MAPK12; mitogen-activated protein kinase 12 isoform X2 [KO:K04441] [EC:2.7.11.24]
101416217  MAPK11; mitogen-activated protein kinase 11 isoform X1 [KO:K04441] [EC:2.7.11.24]
101417876  LAT; linker for activation of T-cells family member 1 [KO:K07362]
101411498  PLCG1; 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 [KO:K01116] [EC:3.1.4.11]
101435854  PPP3CB; serine/threonine-protein phosphatase 2B catalytic subunit beta isoform isoform X1 [KO:K04348] [EC:3.1.3.16]
101420075  PPP3CC; LOW QUALITY PROTEIN: serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform [KO:K04348] [EC:3.1.3.16]
101427629  PPP3CA; serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform isoform X1 [KO:K04348] [EC:3.1.3.16]
101440970  calcineurin subunit B type 2 [KO:K06268]
101441784  RASGRP1; RAS guanyl-releasing protein 1 isoform X1 [KO:K04350]
101415501  CD28; T-cell-specific surface glycoprotein CD28 [KO:K06470]
101410614  PRKCQ; protein kinase C theta type [KO:K18052] [EC:2.7.11.13]
Compound
C00076  Calcium cation
C00165  Diacylglycerol
C01245  D-myo-Inositol 1,4,5-trisphosphate
C05981  Phosphatidylinositol-3,4,5-trisphosphate
Reference
  Authors
Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ
  Title
PD-L1.
  Journal
J Clin Pathol 71:189-194 (2018)
DOI:10.1136/jclinpath-2017-204853
Reference
  Authors
Zhou TC, Sankin AI, Porcelli SA, Perlin DS, Schoenberg MP, Zang X
  Title
A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
  Journal
Urol Oncol 35:14-20 (2017)
DOI:10.1016/j.urolonc.2016.10.004
Reference
  Authors
Wang Y, Wang H, Yao H, Li C, Fang JY, Xu J
  Title
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion.
  Journal
Front Pharmacol 9:536 (2018)
DOI:10.3389/fphar.2018.00536
Reference
  Authors
Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, Wu X, Ma J, Zhou M, Li X, Li Y, Li G, Xiong W, Guo C, Zeng Z
  Title
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
  Journal
Mol Cancer 18:10 (2019)
DOI:10.1186/s12943-018-0928-4
Reference
  Authors
Bardhan K, Anagnostou T, Boussiotis VA
  Title
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation.
  Journal
Front Immunol 7:550 (2016)
DOI:10.3389/fimmu.2016.00550
Reference
  Authors
Shi Y
  Title
Regulatory mechanisms of PD-L1 expression in cancer cells.
  Journal
Cancer Immunol Immunother 67:1481-1489 (2018)
DOI:10.1007/s00262-018-2226-9
Reference
  Authors
Zerdes I, Matikas A, Bergh J, Rassidakis GZ, Foukakis T
  Title
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.
  Journal
Oncogene 37:4639-4661 (2018)
DOI:10.1038/s41388-018-0303-3
Reference
  Authors
Chen J, Jiang CC, Jin L, Zhang XD
  Title
Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
  Journal
Ann Oncol 27:409-16 (2016)
DOI:10.1093/annonc/mdv615
Reference
  Authors
Glodde N, Holzel M
  Title
RAS and PD-L1: A Masters' Liaison in Cancer Immune Evasion.
  Journal
Immunity 47:1007-1009 (2017)
DOI:10.1016/j.immuni.2017.12.001
Reference
  Authors
Ritprajak P, Azuma M
  Title
Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma.
  Journal
Oral Oncol 51:221-8 (2015)
DOI:10.1016/j.oraloncology.2014.11.014
Reference
  Authors
Nirschl CJ, Drake CG
  Title
Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy.
  Journal
Clin Cancer Res 19:4917-24 (2013)
DOI:10.1158/1078-0432.CCR-12-1972
Reference
  Authors
Saeidi A, Zandi K, Cheok YY, Saeidi H, Wong WF, Lee CYQ, Cheong HC, Yong YK, Larsson M, Shankar EM
  Title
T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses.
  Journal
Front Immunol 9:2569 (2018)
DOI:10.3389/fimmu.2018.02569
Reference
  Authors
Sharpe AH, Pauken KE
  Title
The diverse functions of the PD1 inhibitory pathway.
  Journal
Nat Rev Immunol 18:153-167 (2018)
DOI:10.1038/nri.2017.108
Reference
  Authors
Boussiotis VA
  Title
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
  Journal
N Engl J Med 375:1767-1778 (2016)
DOI:10.1056/NEJMra1514296
Reference
  Authors
Arasanz H, Gato-Canas M, Zuazo M, Ibanez-Vea M, Breckpot K, Kochan G, Escors D
  Title
PD1 signal transduction pathways in T cells.
  Journal
Oncotarget 8:51936-51945 (2017)
DOI:10.18632/oncotarget.17232
Reference
  Authors
Zuazo M, Gato-Canas M, Llorente N, Ibanez-Vea M, Arasanz H, Kochan G, Escors D
  Title
Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy.
  Journal
Ann Transl Med 5:385 (2017)
DOI:10.21037/atm.2017.06.11
Reference
  Authors
Patsoukis N, Li L, Sari D, Petkova V, Boussiotis VA
  Title
PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2.
  Journal
Mol Cell Biol 33:3091-8 (2013)
DOI:10.1128/MCB.00319-13
Reference
  Authors
Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X
  Title
New immunotherapies targeting the PD-1 pathway.
  Journal
Trends Pharmacol Sci 36:587-95 (2015)
DOI:10.1016/j.tips.2015.06.005
Reference
  Authors
Ok CY, Young KH
  Title
Targeting the programmed death-1 pathway in lymphoid neoplasms.
  Journal
Cancer Treat Rev 54:99-109 (2017)
DOI:10.1016/j.ctrv.2017.01.009
Related
pathway
dnm04010  MAPK signaling pathway
dnm04020  Calcium signaling pathway
dnm04066  HIF-1 signaling pathway
dnm04151  PI3K-Akt signaling pathway
dnm04514  Cell adhesion molecules
dnm04620  Toll-like receptor signaling pathway
dnm04660  T cell receptor signaling pathway
KO pathway
ko05235   
LinkDB

DBGET integrated database retrieval system